Barclays’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-130,434
| Closed | -$8.88M | – | 5616 |
|
|
2022
Q3 | $8.88M | Sell |
130,434
-461,042
| -78% | -$25.4M | 0.01% | 900 |
|
|
2022
Q2 | $18.9M | Buy |
591,476
+530,438
| +869% | +$15.5M | 0.01% | 752 |
|
|
2022
Q1 | $2.11M | Sell |
61,038
-14,150
| -19% | -$423K | ﹤0.01% | 1823 |
|
|
2021
Q4 | $2.2M | Sell |
75,188
-5,516
| -7% | -$171K | ﹤0.01% | 2331 |
|
|
2021
Q3 | $2.06M | Sell |
80,704
-16,067
| -17% | -$472K | ﹤0.01% | 2332 |
|
|
2021
Q2 | $3.39M | Buy |
96,771
+20,722
| +27% | +$809K | ﹤0.01% | 1832 |
|
|
2021
Q1 | $3.1M | Sell |
76,049
-34,692
| -31% | -$1.59M | ﹤0.01% | 1918 |
|
|
2020
Q4 | $4.8M | Buy |
110,741
+38,144
| +53% | +$1.88M | ﹤0.01% | 1547 |
|
|
2020
Q3 | $4M | Buy |
72,597
+61,898
| +579% | +$3.93M | ﹤0.01% | 1549 |
|
|
2020
Q2 | $675K | Sell |
10,699
-85,008
| -89% | -$5.83M | ﹤0.01% | 3089 |
|
|
2020
Q1 | $4.89M | Sell |
95,707
-46,892
| -33% | -$3.14M | ﹤0.01% | 1488 |
|
|
2019
Q4 | $11.3M | Buy |
142,599
+109,179
| +327% | +$6.47M | 0.01% | 1302 |
|
|
2019
Q3 | $1.62M | Sell |
33,420
-22,258
| -40% | -$1.16M | ﹤0.01% | 3120 |
|
|
2019
Q2 | $2.93M | Buy |
55,678
+38,015
| +215% | +$2.18M | ﹤0.01% | 2462 |
|
|
2019
Q1 | $935K | Sell |
17,663
-1,574
| -8% | -$77.3K | ﹤0.01% | 3475 |
|
|
2018
Q4 | $789K | Sell |
19,237
-21,793
| -53% | -$817K | ﹤0.01% | 3360 |
|
|
2018
Q3 | $1.56M | Buy |
41,030
+35,736
| +675% | +$1.58M | ﹤0.01% | 3169 |
|
|
2018
Q2 | $239K | Sell |
5,294
-24,873
| -82% | -$1.13M | ﹤0.01% | 4570 |
|
|
2018
Q1 | $1.46M | Sell |
30,167
-61,626
| -67% | -$3.44M | ﹤0.01% | 2789 |
|
|
2017
Q4 | $3.61M | Sell |
91,793
-511
| -0.6% | -$19.1K | ﹤0.01% | 1906 |
|
|
2017
Q3 | $2.87M | Sell |
92,304
-1,472
| -2% | -$41.4K | ﹤0.01% | 2000 |
|
|
2017
Q2 | $2.56M | Sell |
93,776
-3,604
| -4% | -$107K | ﹤0.01% | 2037 |
|
|
2017
Q1 | $3.59M | Buy |
97,380
+70,057
| +256% | +$1.76M | ﹤0.01% | 1578 |
|
|
2016
Q4 | $394K | Buy |
27,323
+24,532
| +879% | +$431K | ﹤0.01% | 3609 |
|
|
2016
Q3 | $64K | Buy |
2,791
+381
| +16% | +$7.26K | ﹤0.01% | 4835 |
|
|
2016
Q2 | $40K | Buy |
+2,410
| New | +$48.6K | ﹤0.01% | 4960 |
|
|
2015
Q4 | – | Sell |
-1,620
| Closed | -$68K | – | 6761 |
|
|
2015
Q3 | $68K | Buy |
+1,620
| New | +$76.4K | ﹤0.01% | 4845 |
|
Other funds holding GBT
Barclays's GBT Position: Q4 2022 in Review
Barclays sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 130,434 shares — an estimated $8.88M sold.
Barclays first reported a position in GBT in Q3 2015 and held it in 27 quarters. The position peaked at $18.9M in Q2 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Barclays reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Barclays sold 130,434 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $8.88M.
- Barclays first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 27 quarters.
- Barclays's Global Blood Therapeutics, Inc. position peaked at $18.9M in Q2 2022.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.